Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100
On August 28, 2026, Liquidia Corp (LQDA) shares experienced a decline of 3.1%, bringing the current price to $67.63. This movement occurs within a 52-week range
LQDA - Liquidia Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$98.11
DETAILS
HIGH:
$130.00
LOW:
$36.00
MEDIAN:
$108.00
CONSENSUS:
$98.11
UPSIDE:
44.94%
Stock News
Liquidia: A Linear Launch Priced For Exponential Growth
Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors
On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA
Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company's stock, valued at approximately $1,993,000. Other institutional investors and hedge funds
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
Why Liquidia Stock Was Diving This Week
The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Q2 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.
Liquidia Corporation Reports Second Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET
Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.
3 Top Ranked Stocks Breaking Out Now
Lenovo Group, Victoria's Secret and Liquidia Corporation are three stocks from very different industries benefitting from the same catalysts.
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Price Targets
Liquidia price target raised to $106 from $68 at Raymond James
$106.00
(was $78.45)
Raymond James
Liquidia price target raised to $108 from $62 at Wells Fargo
$108.00
(was $78.79)
Wells Fargo
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$130.00
(was $89.03)
RBC Capital
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$129.00
(was $89.03)
Piper Sandler
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$36.00
(was $89.03)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $130 at H.C. Wainwright
$130.00
(was $89.03)
Stephens
Liquidia price target raised to $130 from $75 at H.C. Wainwright
$130.00
(was $89.11)
H.C. Wainwright
Liquidia price target raised to $109 from $59 at BTIG
$109.00
(was $71.07)
BTIG
Liquidia price target raised to $75 from $67 at H.C. Wainwright
$75.00
(was $62.54)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$28.00
(was $62.54)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $75 at H.C. Wainwright
$75.00
(was $62.54)
Oppenheimer
Raymond James sees positive readthrough for Liquidia from Hikma v. Amarin
$68.00
(was $62.54)
Raymond James
Liquidia price target raised to $67 from $55 at H.C. Wainwright
$67.00
(was $53.50)
Andrew Fein
·
H.C. Wainwright
Liquidia price target raised to $62 from $51 at Wells Fargo
$62.00
(was $53.13)
Wells Fargo
Liquidia price target raised to $60 from $57 at Jefferies
$60.00
(was $53.13)
Amy Li
·
Jefferies
Liquidia price target raised to $55 from $45 at Jefferies
$55.00
(was $37.02)
Amy Li
·
Jefferies
Liquidia price target raised to $50 from $35 at H.C. Wainwright
$50.00
(was $27.32)
H.C. Wainwright
Liquidia Technologies (LQDA) PT Raised to $47 at Raymond James
$47.00
(was $25.22)
Ryan Deschner
·
Raymond James
Liquidia price target raised to $45 from $43 at Jefferies
$45.00
(was $25.22)
Jefferies
Liquidia downgraded to Underperform from Perform at Oppenheimer
$13.00
(was $17.03)
Andreas Argyrides
·
Oppenheimer